Table 5.
univariate and multivariate analysis for OS and DFS of the patients
| Factors | Overall survival (OS) | Disease-free survival (DFS) | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p-value | HR | 95%CI | p-value | |
| Univariate analysis | ||||||
| Age (yrs) < 40 vs ≥40 | 2.2 | 1.0–4.8 | 0.038 | 2.8 | 1.3–5.9 | 0.006 |
| B symptoms -ve vs + ve | 1.1 | 0.5–2.4 | 0.78 | 1.23 | 0.6–2.5 | 0.58 |
| Bulky disease + ve vs -ve | 1.8 | 0.6–5.1 | 0.28 | 0.61 | 0.24–1.6 | 0.31 |
| IPS Low vs High | 1.9 | 0.9–4.0 | 0.10 | 1.5 | 0.7–3.2 | 0.26 |
| Gender M vs F | 1.2 | 0.6–2.5 | 0.59 | 1.23 | 0.6–2.5 | 0.51 |
| Pathology | 0.9 | 0.5–1.6 | 0.73 | 0.86 | 0.49–1.5 | 0.61 |
| Stage early vs late | 2.6 | 1.2–5.8 | 0.02 | 2.2 | 1.0–4.5 | 0.04 |
| CD20 -ve vs + ve | 0.15 | 0.05–0.29 | < 0.001 | 0.15 | 0.07–0.33 | < 0.001 |
| CD68 (mRNA) –ve vs + ve | 13.2 | 3.9–43.7 | < 0.001 | 6.6 | 2.7–16.0 | < 0.001 |
| CD68 (IHC) –ve vs + ve | 4.7 | 2.6–8.2 | < 0.001 | 4.0 | 2.4–6.6 | < 0.001 |
| CD68 CC < 10 vs ≥10 cells | 12.2 | 4.2–32.3 | < 0.001 | 7.1 | 3.1–16.4 | < 0.001 |
| Multivariate analysis | ||||||
| Age (yrs) < 40 vs ≥40 | 2.5 | 1.1–5.6 | 0.02 | 3.2 | 1.5–7.0 | 0.004 |
| Stage early vs late | 2.2 | 0.8–6.1 | 0.11 | 1.8 | 0.69–4.5 | 0.23 |
| CD20 -ve vs + ve | 0.24 | 0.09–0.69 | 0.008 | 0.29 | 0.11–0.74 | 0.01 |
| CD68 (mRNA)–ve vs + ve | 2.6 | 0.28–24.6 | 0.40 | 5.8 | 0.90–32.0 | 0.07 |
| CD68 (IHC) –ve vs + ve | 5.2 | 0.65–41.3 | 01.2 | 8.2 | 1.6–41.8 | 0.01 |
| CD68+ cells (FCM) < 20 vs ≥20 cells | 9.5 | 1.8–51.5 | 0.009 | 7.7 | 1.7–33.7 | 0.007 |